141 related articles for article (PubMed ID: 21157138)
21. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
22. EBV load in whole blood correlates with LMP2 gene expression after pediatric heart transplantation or allogeneic hematopoietic stem cell transplantation.
Ruf S; Behnke-Hall K; Gruhn B; Reiter A; Wagner HJ
Transplantation; 2014 May; 97(9):958-64. PubMed ID: 24389909
[TBL] [Abstract][Full Text] [Related]
23. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
[TBL] [Abstract][Full Text] [Related]
24. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
25. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
26. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.
Sirvent-Von Bueltzingsloewen A; Morand P; Buisson M; Souillet G; Chambost H; Bosson JL; Bordigoni P
Bone Marrow Transplant; 2002 Jan; 29(1):21-8. PubMed ID: 11840140
[TBL] [Abstract][Full Text] [Related]
27. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.
Stevens SJ; Pronk I; Middeldorp JM
J Clin Microbiol; 2001 Apr; 39(4):1211-6. PubMed ID: 11283029
[TBL] [Abstract][Full Text] [Related]
28. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
[TBL] [Abstract][Full Text] [Related]
29. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
31. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
33. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.
Cesaro S; Pegoraro A; Tridello G; Calore E; Pillon M; Varotto S; Abate D; Barzon L; Mengoli C; Carli M; Messina C
Transplantation; 2010 Jun; 89(12):1533-40. PubMed ID: 20463647
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
35. Molecular epidemiology of Epstein-Barr virus in adult kidney transplant recipients.
Cavallo R; Elia M; Gruosso V; Curtoni A; Costa C; Bergallo M
Transplant Proc; 2010 Sep; 42(7):2527-30. PubMed ID: 20832536
[TBL] [Abstract][Full Text] [Related]
36. Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
Marzolini MAV; Wilson AJ; Sanchez E; Carpenter B; Chakraverty R; Hough R; Kottaridis P; Morris EC; Thomson KJ; Peggs KS
Transplant Cell Ther; 2021 Aug; 27(8):682.e1-682.e12. PubMed ID: 33962069
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections].
Karadağ Geçgel S; Ersoy A; Sevinir BB; Sınırtaş M; Göral G
Mikrobiyol Bul; 2012 Oct; 46(4):594-606. PubMed ID: 23188573
[TBL] [Abstract][Full Text] [Related]
38. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
[TBL] [Abstract][Full Text] [Related]
39. The Viral Load of Epstein-Barr Virus in Blood of Children after Hematopoietic Stem Cell Transplantation.
Wang WJ; Feng SQ; He F; Du HJ; Feng M; Wang RF; Mei GY; Liu M; Liu R; Yao HL; Han J
Biomed Environ Sci; 2022 Sep; 35(9):804-810. PubMed ID: 36189995
[TBL] [Abstract][Full Text] [Related]
40. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
